ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Conversion from Tacrolimus to Belatacept in Pancreas Transplant Alone Recipients with Chronic Kidney Disease.

A. Sharfuddin, J. Chen, M. Yaqub, T. Taber, J. Powelson, D. Mishler, M. Goble, J. Fridell, O. Adebiyi, M. Mujtaba.

Medicine/Nephrology & Surgery/Transplant, Indiana University, Indianapolis.

Meeting: 2016 American Transplant Congress

Abstract number: 486

Keywords: Calcineurin, Kidney, Pancreas transplantation, Renal dysfunction

Session Information

Session Name: Concurrent Session: Clinical Pancreas Transplantation 2

Session Type: Concurrent Session

Date: Tuesday, June 14, 2016

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:18pm-5:30pm

Location: Room 210

Background: CNI toxicity is a well known risk factor for chronic kidney disease and ESRD in organ transplants. We report our experience in converting Pancreas Transplant Alone (PTA) recipients from tacrolimus to Belatacept in order to avoid further worsening of kidney function.

Methods: Six (mean age = 52.8+/-7, 5 Females, 5 Caucasians) patients with PAT initially maintained on tacrolimus, sirolimus and mycophenolate with biopsy proven native chronic kidney atrophy & fibrosis consistent with CNI toxicity were enrolled in a 1 year prospective intention to treat IRB approved study. Tacrolimus was weaned off over 60 days. Patients were maintained on a steroid free regimen of Belatacept, Sirolimus (level 3-6ng/ml) and Mycophenolate.

Results: Median time from PAT to conversion was 5.9 years(range 2.5-9.5). Pre-conversion the mean eGFR was 28.9+/-9, that modestly improved over 12 months to an eGFR of 32.7+/-11. One patient could not tolerate the oral immunosuppression regimen and another patient was non compliant and hence did not complete the study. The remaining 4 cases completed 12 months, of which only 1 case experienced elevation of Lipase requiring steroid therapy with subsequent successful response and continued on the same regimen with Belatacept. Serum glucose, C-peptide and Hemoglobin A1c levels remained unchanged over the study period. There was no incidence of BK, CMV, EBV, PTLD or Donor Specific Antibody (DSA) noted during prospective monitoring. No other new clinically significant event was noted with the use of this regimen over these 12 months. These 4 cases now have each completed a mean follow up of 17 months without any other new significant events with stable renal function and proteinuria.

Conclusions: Chronic kidney disease progression due to CNI toxicity can likely be stabilized by converting to Belatacept in PTA recipients. Larger and longer term studies are needed to ensure the safety of this approach in PTA recipients in order to preserve kidney function.

CITATION INFORMATION: Sharfuddin A, Chen J, Yaqub M, Taber T, Powelson J, Mishler D, Goble M, Fridell J, Adebiyi O, Mujtaba M. Conversion from Tacrolimus to Belatacept in Pancreas Transplant Alone Recipients with Chronic Kidney Disease. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Sharfuddin A, Chen J, Yaqub M, Taber T, Powelson J, Mishler D, Goble M, Fridell J, Adebiyi O, Mujtaba M. Conversion from Tacrolimus to Belatacept in Pancreas Transplant Alone Recipients with Chronic Kidney Disease. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/conversion-from-tacrolimus-to-belatacept-in-pancreas-transplant-alone-recipients-with-chronic-kidney-disease/. Accessed May 21, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences